Gabriel S Macedo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6684865/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genomic characterization of small cell carcinomas of the uterine cervix. Molecular Oncology, 2022, 16, 833-845.	4.6	14
2	Prevalence of the Brazilian TP53 Founder c.1010C>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?. Frontiers in Genetics, 2021, 12, 606537.	2.3	2
3	Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil. PLoS ONE, 2021, 16, e0251639.	2.5	4
4	A novel DMD intronic alteration: a potentially disease-causing variant of an intermediate muscular dystrophy phenotype. Acta Myologica, 2021, 40, 93-100.	1.5	0
5	MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers. Cancer Genetics, 2020, 240, 54-58.	0.4	5
6	Skin pigmentation polymorphisms associated with increased risk of melanoma in a case-control sample from southern Brazil. BMC Cancer, 2020, 20, 1069.	2.6	9
7	The role of ESCO2, SALL4 and TBX5 genes in the susceptibility to thalidomide teratogenesis. Scientific Reports, 2019, 9, 11413.	3.3	11
8	Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country. Journal of Global Oncology, 2019, 5, 1-9.	0.5	13
9	Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. Genetics and Molecular Biology, 2019, 42, 215-231.	1.3	14
10	p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers. Familial Cancer, 2018, 17, 269-274.	1.9	11
11	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget, 2018, 9, 20617-20630.	1.8	36
12	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. Histopathology, 2017, 71, 480-487.	2.9	2
13	Abstract 3379: Massively parallel sequencing analysis of breast adenomyoepitheliomas reveals the heterogeneity of the disease and identifies a subset driven byHRAShotspot mutations. , 2017, , .		1
14	Comparison of multiple genotyping methods for the identification of the cancer predisposing founder mutation p.R337H in TP53. Genetics and Molecular Biology, 2016, 39, 203-209.	1.3	8
15	miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma. Pancreas, 2016, 45, 84-92.	1.1	56
16	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <i><scp>TERT</scp></i> promoter hotspot mutations and <i>TERT</i> gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	4.5	102
17	Uterine adenosarcomas are mesenchymal neoplasms. Journal of Pathology, 2016, 238, 381-388.	4.5	94
18	Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome. Cancer Genetics, 2016, 209, 97-106.	0.4	19

GABRIEL S MACEDO

#	Article	IF	CITATIONS
19	The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-4056.	7.0	119
20	Abstract 100: The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers. , 2016, , .		1
21	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. Histopathology, 2015, 67, 529-537.	2.9	37
22	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. Journal of the National Cancer Institute, 2015, 108, djv427.	6.3	164
23	Abstract 804: Energetic metabolism and DNA damage response in fibroblasts from Li-Fraumeni syndrome patients: new insights into the molecular mechanisms of the disease. , 2015, , .		0
24	Increased Oxidative Damage in Carriers of the Germline TP53 p.R337H Mutation. PLoS ONE, 2012, 7, e47010.	2.5	21
25	Polymorphisms of the <i>UCP2</i> gene are associated with proliferative diabetic retinopathy in patients with diabetes mellitus. Clinical Endocrinology, 2010, 72, 612-619.	2.4	51